Chattopadhyay M, Mata M, Goss J, Wolfe D, Huang S, Glorioso J C, Fink D J
Department of Neurology, University of Michigan Health System, 1500 East Medical Center Drive, Room 1914 TC, Ann Arbor, MI 48109 0316, USA.
Diabetologia. 2007 Jul;50(7):1550-8. doi: 10.1007/s00125-007-0702-4. Epub 2007 May 17.
AIMS/HYPOTHESIS: The aim of this study was to determine whether prolonged expression of neurotrophin-3 (NT-3) in mice, achieved by herpes simplex virus (HSV)-mediated gene transfer with gene expression under the control of an HSV latency promoter, can provide protection against the progression of diabetic neuropathy over a 6 month period.
Mice with diabetes induced by streptozotocin were inoculated s.c. into both hind feet with a non-replicating HSV vector containing the coding sequence for NT-3 under the control of the HSV latency-associated promoter 2 (LAP2) elements or with a control vector. Nerve function was evaluated by electrophysiological and behavioural measures over the course of 6 months after the onset of diabetes.
Animals inoculated with the NT-3-expressing vector, but not animals inoculated with control vector, showed preservation of sensory and motor nerve amplitude and conduction velocity measured electrophysiologically, small fibre sensory function assessed by withdrawal from heat, autonomic function measured by pilocarpine-induced sweating, skin innervation assessed by protein gene product 9.5 staining of axons, and density of calcitonin gene-related peptide terminals in the spinal cord measured by immunohistochemistry 5.5 months after vector inoculation.
CONCLUSIONS/INTERPRETATION: These results indicate that the continuous production of NT-3 by LAP2-driven expression of the transgene from an HSV vector over a 6 month period protects against progression of diabetic neuropathy in mice, and provide a proof-of-principle demonstration for the development of a novel therapy for preventing the progression of diabetic neuropathy.
目的/假设:本研究的目的是确定通过单纯疱疹病毒(HSV)介导的基因转移,并在HSV潜伏启动子控制下进行基因表达,使神经营养因子3(NT-3)在小鼠体内长期表达,是否能在6个月内预防糖尿病神经病变的进展。
用链脲佐菌素诱导糖尿病的小鼠,通过皮下注射,在两只后足接种含有在HSV潜伏相关启动子2(LAP2)元件控制下的NT-3编码序列的非复制型HSV载体,或接种对照载体。在糖尿病发病后的6个月内,通过电生理和行为学方法评估神经功能。
接种表达NT-3载体的动物,而非接种对照载体的动物,在接种载体5.5个月后,电生理测量显示感觉和运动神经振幅及传导速度得以保留,通过热刺激撤离评估的小纤维感觉功能、通过毛果芸香碱诱导出汗测量的自主神经功能、通过轴突蛋白基因产物9.5染色评估的皮肤神经支配,以及通过免疫组织化学测量的脊髓中降钙素基因相关肽终末密度均得以保留。
结论/解读:这些结果表明,HSV载体通过LAP2驱动转基因表达持续产生NT-3达6个月,可预防小鼠糖尿病神经病变的进展,并为开发预防糖尿病神经病变进展的新疗法提供了原理证明。